New malaria shot could offer months of protection
NCT ID NCT07548021
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This early-stage study tests a single injection of MMV371, a long-acting medicine, to see if it safely prevents malaria in healthy adults and teens aged 12-50 in Rwanda. About 80 participants will get either the study drug or a placebo, and researchers will monitor them for 24 weeks to check for side effects and measure drug levels in the body. The goal is to find a new way to protect against malaria with just one shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rinda Ubuzima
Kigali, Rwanda
Conditions
Explore the condition pages connected to this study.